Fig. 10From: Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC)Summary of RECIST and CODRP index-based drug sensitivity test results. (A) Comparison of CODRP index-based drug sensitivity test and patient’s RECIST-based drug treatment response assessment results. (B) LC_01T, 02T, 03PE and 09PE patients showed effects on the prescribed drugs (alectinib and brigatinib), and sensitive drug responses were also analyzed in organoid models; LC_08PE patient had no therapeutic effect on the prescribed drug (alectinib) and showed drug resistance in an organoid modelBack to article page